Contact us

Contact should be directed to the following:

Business inquiries: Managing Director, Gunnar Sælid

Scientific matters:
Infectious diseases
- John S. Svendsen, PhD
Oncology - Øystein Rekdal, PhD

Business development: Anders Fugelli, PhD

Company head office:
Lytix Biopharma AS
P.O. Box 6447,
NO-9294 Tromsø, Norway

Oslo office:
Lytix Biopharma AS
Gaustadalleen 21
NO-0349 Oslo, Norway

E-mail:  post@lytixbiopharma.com
Phone:  +47 77 67 55 00
Fax: +47 77 67 55 01




September 01, 2010:
- Approval to start Phase IIa clinical trial with Lytixar™ (LTX-109)
Oslo, Norway and Seoul, Korea, June 09, 2010:
- Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial
May 20, 2010:
- Update on the Phase I clinical trials of Oncopore™ (LTX-315) for the treatment of cancer.
May 20, 2010:
- Approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial